SCHEMBL3483796

SCHEMBL3483796

Nc1ccc(Oc2ccc3ccnn3c2)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 2/20 0.41
DRD2 P14416 3/20 0.37
DRD4 P21917 3/20 0.37
DRD3 P35462 3/20 0.37
HTR2A P28223 2/20 0.36
SLC6A4 P31645 1/20 0.36
PNLIP P16233 1/20 0.36
MPO P05164 1/20 0.35
TPO P07202 1/20 0.35
EPX P11678 1/20 0.35
LPO P22079 1/20 0.35
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
CYP3A4 P08684 2/20 0.33
TSHR P16473 1/20 0.33
NPC1 O15118 1/20 0.33
EGFR P00533 1/20 0.33
ERBB2 P04626 1/20 0.33
DRD1 P21728 1/20 0.33
SYK P43405 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21563126 0.83 EGFR (0.42) DRD2DRD4DRD3HTR2ASLC6A4
SCHEMBL3484150 0.82 DRD2 (0.38) PDE7ADRD2DRD4DRD3HTR2A
SCHEMBL15701545 0.82 CYP2C19 (0.39) DRD2DRD4DRD3HTR2ADRD1
SCHEMBL3484788 0.80 PDE7A (0.56) PDE7AMEN1KMT2ACYP3A4NPC1
SCHEMBL24995754 0.78 DYRK1A (0.42) PDE7AHTR2ASLC6A4PNLIPMPO
SCHEMBL4318630 0.75 PDE7A (0.63) PDE7AHTR2ASLC6A4PNLIPMEN1
SCHEMBL631854 0.72 PDE7A (0.49) PDE7AHTR2ASLC6A4PNLIPMPO
SCHEMBL3483989 0.72 AXL (0.41) DRD2DRD4DRD3MEN1KMT2A
SCHEMBL1374919 0.72 CYP3A4 (0.58) PDE7APNLIPMEN1KMT2ACYP3A4
SCHEMBL554722 0.72 MAOA (0.61) PDE7AHTR2ASLC6A4PNLIPMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2103620-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND ERBB2, ROS1, FLT3 PDE7A 4340/4885DRD2 1841/4885DRD4 2385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.